Drug Profile
Trastuzumab biosimilar - International Biotech Center Generium
Alternative Names: GNR-027Latest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator International Biotech Center Generium
- Developer International Biotechnology Center Generium
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Breast cancer in Russia (Parenteral)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Breast-cancer in Russia (Parenteral)
- 26 Oct 2015 Preclinical trials in Breast cancer in Russia (Parenteral) before October 2015